RATIONALE: The phenomenon of sensitization has been theoretically implicated in mediating various aspects of drug addiction. Recent dose-response studies demonstrated that pretreatment with the putative antiaddictive agent, ibogaine (IBO), and a synthetic iboga alkaloid congener, 18-methoxycoronaridine (18-MC), increase the potency of cocaine to elicit behavioral sensitization, an effect proposed to contribute, in part, to their ability to attenuate drug self-administration. OBJECTIVES: As abuse of the methylated amphetamine derivative, methamphetamine (METH), is a growing public health concern, the present study determined the interactions between IBO and 18-MC and the expression of METH-induced behavioral sensitization. METHODS: The effects of pretreatment with 18-MC (40 mg/kg, IP, 19 h earlier) on the expression of METH-induced locomotion (0, 0.25, 0.5, 1 and 2 mg/kg, IP) and the effects of pretreatment with either IBO or 18-MC on the expression of METH-induced stereotypy (2 and 4 mg/kg, IP) were assessed in rats treated chronically with either METH (4 mg/kg daily for 7 days) or saline. RESULTS: Compared to vehicle-pretreated controls, 18-MC produced an overall enhancement in METH-induced locomotion in rats treated chronically, but not acutely, with METH. In addition, both iboga agents increased the stereotypic response to METH. CONCLUSIONS: Iboga agents augment both the locomotor and stereotypic effects of METH in a manner consistent with previous reports for cocaine. Thus, it appears that iboga agents interact in a similar manner with the neural mechanisms mediating motor hyperactivity induced by the chronic administration of stimulant drugs.
RATIONALE: The phenomenon of sensitization has been theoretically implicated in mediating various aspects of drug addiction. Recent dose-response studies demonstrated that pretreatment with the putative antiaddictive agent, ibogaine (IBO), and a synthetic iboga alkaloid congener, 18-methoxycoronaridine (18-MC), increase the potency of cocaine to elicit behavioral sensitization, an effect proposed to contribute, in part, to their ability to attenuate drug self-administration. OBJECTIVES: As abuse of the methylated amphetamine derivative, methamphetamine (METH), is a growing public health concern, the present study determined the interactions between IBO and 18-MC and the expression of METH-induced behavioral sensitization. METHODS: The effects of pretreatment with 18-MC (40 mg/kg, IP, 19 h earlier) on the expression of METH-induced locomotion (0, 0.25, 0.5, 1 and 2 mg/kg, IP) and the effects of pretreatment with either IBO or 18-MC on the expression of METH-induced stereotypy (2 and 4 mg/kg, IP) were assessed in rats treated chronically with either METH (4 mg/kg daily for 7 days) or saline. RESULTS: Compared to vehicle-pretreated controls, 18-MC produced an overall enhancement in METH-induced locomotion in rats treated chronically, but not acutely, with METH. In addition, both iboga agents increased the stereotypic response to METH. CONCLUSIONS: Iboga agents augment both the locomotor and stereotypic effects of METH in a manner consistent with previous reports for cocaine. Thus, it appears that iboga agents interact in a similar manner with the neural mechanisms mediating motor hyperactivity induced by the chronic administration of stimulant drugs.
Authors: Karen K Szumlinski; Kevin D Lominac; Rianne R Campbell; Matan Cohen; Elissa K Fultz; Chelsea N Brown; Bailey W Miller; Sema G Quadir; Douglas Martin; Andrew B Thompson; Georg von Jonquieres; Matthias Klugmann; Tamara J Phillips; Tod E Kippin Journal: Biol Psychiatry Date: 2016-10-13 Impact factor: 13.382
Authors: Kevin D Lominac; Sema G Quadir; Hannah M Barrett; Courtney L McKenna; Lisa M Schwartz; Paige N Ruiz; Melissa G Wroten; Rianne R Campbell; Bailey W Miller; John J Holloway; Katherine O Travis; Ganesh Rajasekar; Dan Maliniak; Andrew B Thompson; Lawrence E Urman; Tod E Kippin; Tamara J Phillips; Karen K Szumlinski Journal: Eur J Neurosci Date: 2016-02-22 Impact factor: 3.386
Authors: Marek Schwendt; Angelica Rocha; Ronald E See; Alejandra M Pacchioni; Jacqueline F McGinty; Peter W Kalivas Journal: J Pharmacol Exp Ther Date: 2009-07-31 Impact factor: 4.030
Authors: Craig P Motbey; Emily Karanges; Kong M Li; Shane Wilkinson; Adam R Winstock; John Ramsay; Callum Hicks; Michael D Kendig; Naomi Wyatt; Paul D Callaghan; Iain S McGregor Journal: PLoS One Date: 2012-09-18 Impact factor: 3.240